"Test, test, test" has been the leitmotif of the World Health Organization (WHO) since the start of the pandemic. However, mass screening requires a rapid, simple and effective detection test. To answer this question, french researchers carried out a real race against the clock in the laboratory in order to produce and market this test in record time. This one, called EasyCOV1, requires a saliva sample and provides the results in 1 hour. Back on this test and its mode of action.
In mid-May, the American company Moderna announced that the vaccine developed against Covid-19 had triggered an immune response in 8 patients. These patients secreted antibodies in an amount comparable to those seen in infected patients and recovered from the coronavirus. Among the panoply of vaccine strategies currently being tested, to which category does Moderna belong?
The research sectors particularly impacted by the pandemic are beginning to be identified. David Knapp, Principal Investigator at IRIC, in collaboration with David G. Kent (University of York) and Nagarajan Kannan (Mayo Clinic), highlight the consequences of the health crisis on early-career investigators and clinical trials.